Evidence map›Paper›PMID 40365451›Full record

ArticlePathology oncology research : POR2025

HER2 expression in different cell lines at different inoculation sites assessed by [

Toàn Minh Ngô, Adrienn Vágner, Gábor Nagy, Gábor Ország, Tamás Nagy, Zoltán Szoboszlai, Csaba Csikos, Balázs Váradi, György Trencsényi, Gyula Tircsó and 1 more

Abstract read
In one paragraph

Article in Pathology oncology research : POR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Enhanced Tumor-to-Background Contrast with [Pharmaceuticals (Basel, Switzerland) · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Toàn Minh NgôGyula Petrányi Doctoral School of Clinical Immunology and Allergology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Adrienn VágnerScanomed Ltd., Debrecen, Hungary.
Gábor NagyScanomed Ltd., Debrecen, Hungary.
Gábor OrszágScanomed Ltd., Debrecen, Hungary.
Tamás NagyDepartment of Nuclear Medicine, Medical Imaging Clinic, Clinical Centre, University of Debrecen, Debrecen, Hungary.
Zoltán SzoboszlaiScanomed Ltd., Debrecen, Hungary.
Csaba CsikosGyula Petrányi Doctoral School of Clinical Immunology and Allergology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Balázs VáradiDepartment of Physical Chemistry, Institute of Chemistry, Faculty of Science and Technology, University of Debrecen, Debrecen, Hungary.
György TrencsényiGyula Petrányi Doctoral School of Clinical Immunology and Allergology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Gyula TircsóDepartment of Physical Chemistry, Institute of Chemistry, Faculty of Science and Technology, University of Debrecen, Debrecen, Hungary.
Ildikó GaraiGyula Petrányi Doctoral School of Clinical Immunology and Allergology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Positron emission tomography (PET) hybrid imaging targeting HER2 requires antibodies labelled with longer half-life isotopes. With a suitable radiation profile, Methods: PET/MRI and PET/CT were performed on SCID mice bearing orthotopic and ectopic HER2-positive and ectopic HER2-negative tumors at 4, 24, 48, 72, and 120 h post-injection with [ Results: Conclusion: These results suggest that [

Indexed as

Erb-b2 Receptor Tyrosine KinasesMelanomaRadiopharmaceuticalsTrastuzumabAnimalsCell Line, TumorFemaleHumansManganeseMiceMice, SCIDPositron Emission Tomography Computed TomographyTissue DistributionXenograft Model Antitumor AssaysERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesManganeseRadiopharmaceuticalsTrastuzumab52Mnbreast cancerHER2positron emission tomographytrastuzumab

Identifiers

PMID40365451
PMCPMC12069034

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.